论文部分内容阅读
１９９３年６月—１９９６年６月间，作者观察了羟基喜树碱（ＨＣＰＴ）合并氟脲嘧啶（５－ＦＵ）、醛氢叶酸（ＣＦ）治疗晚期大肠癌１９例，并与５－ＦＵ／ＣＦ方案治疗晚期大肠癌１６例相比较，有效率分别是３６．８％（７／１９）和１２．５％（２／１６），虽然治疗组有效率较高，但经统计学处理无显著性差异。两组均未见严重的毒副反应。作者认为，ＨＣＰＴ可选择性抑制ＴｏｐｏＩ，针对性地消除肿瘤耐药，与５－ＦＵ／ＣＦ联合治疗晚期大肠癌，初步观察其近期疗效较好，无毒性增加，值得临床进一步研究。
Between June 1993 and June 1996, the authors observed that HCPT was combined with 5-FU and 5-FU, and 19 patients with advanced colorectal cancer were treated with 5-FU/ Compared with 16 cases of advanced colorectal cancer treated with CF regimen, the effective rates were 36.8% (7/19) and 12.5% (2/16), respectively. Although the treatment group was more effective, it was not statistically significant. Sexual differences. No serious side effects were seen in both groups. The authors believe that HCPT can selectively inhibit TopoI, targeted elimination of tumor drug resistance, and 5-FU/CF in the treatment of advanced colorectal cancer, preliminary observation of its short-term efficacy is good, no increase in toxicity, it is worth further clinical study.